Yield

Yield

On the framework's adjusted basis — reported free cash flow minus stock compensation minus a five-year average of acquisition spend — Cigna converts to roughly $7.5 billion of adjusted FCF on FY2025 filings, a 9.8% yield on the $76.5 billion market cap: 20 basis points short of the 10% default bar, but above it on the three-year average (10.9%) and on consensus forward FCF (11–13%). The balance sheet is moderate (net debt near 1.9x EBITDA), so the 10% line — not the fortress or levered line — applies. The adjustment removes little: Cigna is a cash generator trading near its own long-run ~10% yield, not a reported figure inflated by roll-up accounting.

The adjustment, line by line

The framework does not take reported free cash flow at face value. It removes two recurring drains a cash-flow statement understates: stock-based compensation (a real cost paid in shares, not always added back as its own line) and the ongoing capital a serial acquirer spends to stand still, smoothed as a five-year average. For Cigna the arithmetic starts from operating cash flow less property-and-equipment purchases, both taken straight from the filed statements.

Adjusted FCF = reported FCF (operating cash flow − property & equipment purchases) − same-year SBC − trailing five-year-average acquisitions; all figures $M, derived from company filings. Operating cash flow, capex and acquisitions: FY2025 10-K [1], FY2023 10-K [2], FY2021 10-K [3]; SBC from Note 18 (Employee Incentive Plans): FY2025 [4], FY2023 [5], FY2021 [6].

The FY2025 line reads: operating cash flow of $9,601M less $1,212M of capex is reported FCF of $8,389M [7]; subtract $291M of share-based compensation [8] and a five-year acquisition average of $602M (FY2021–FY2025 acquisitions of $1,833M, $0, $447M, $131M and $597M, divided by five) [9] and adjusted FCF is $7,496M.

What the adjustment does not do here is material to the read. The two deductions together take about $0.9 billion off an $8.4 billion reported figure — roughly an 11% haircut. SBC runs a steady $264–308M a year, small for a company this size [10]; recurring acquisition spend since 2019 has averaged about $600M, dominated by one 2021 bolt-on (the $1,833M MDLIVE-era outlay) rather than a continuous roll-up [11]. This is not a company whose reported cash flow is flattered by serial dealmaking. The one transformational deal — the ~$52 billion Express Scripts acquisition — closed in December 2018, before every window shown here; including it would swamp the average and misstate Cigna's recurring M&A intensity, so the five-year windows deliberately start in 2019.

The yield, three ways

Adjusted FCF ÷ market cap of $76.5B (268.563M shares at $284.85, 22 Jul 2026). Current = FY2025 adjusted FCF $7,496M; 3-year average = FY2023–FY2025 mean adjusted FCF $8,358M; baseline = median of per-year adjusted-FCF yields FY2019–FY2025. Derived from company filings; market cap per the price feed.

The three cuts frame the range. On trailing FY2025 adjusted FCF, the yield is 9.80% ($7,496M ÷ $76,500M). On the three-year average adjusted FCF of $8,358M — smoothing a working-capital-boosted 2023 and a cyclically pressured 2025 — it is 10.93%. And the company's own seven-year distribution of adjusted-FCF yields (each year's adjusted FCF over that year's market cap) carries a median near 10.3%.

Per-year adjusted FCF ÷ same-year market cap (year-end shares × year-end close); FY2019–FY2022 adjusted FCF uses a partial acquisition window (2019 onward) and is approximate. Derived from company filings and the price feed. Cash-flow components: FY2025 [12], FY2021 [13].

The distribution matters because the fortress signature the framework looks for is a jump — a name that sat at a stable 3.5–4% for years and is suddenly offered near 8–9% because the price collapsed while the cash flow held. Cigna does not show that shape. Its adjusted-FCF yield has orbited 10% for most of a decade: near 10–11% in 2019–2020, dipping to ~6.3–6.5% in 2021–2022 when the stock ran to $331 (year-end 2022) even as FCF softened, then back to ~10–10.6% across 2023–2025. The current 9.80% sits just below the seven-year median, not two times above a lower baseline. What the drawdown has done — a 33% fall from the September 2024 peak of $366.85 to the October 2025 trough of $244.41, detailed in the drawdown anatomy (Dislocation) — is move the yield from roughly 7% at the peak ($7.5B on a ~$104B peak market cap) back up toward its own 10% norm. That is a return to baseline, not a dislocation spike above it. The honest read: Cigna clears the bar the way it usually does, not because fear has repriced a fortress.

Which bar applies

The reference line is set by the balance sheet, so it has to be computed before the yield can be judged against it. The framework's rule: net debt at or below zero (or under 0.5x EBITDA) is a fortress, which lowers the bar to ~8–9%; 3.0x or above is levered, raising it to 25%; anything between is moderate, and the 10% default holds.

Cigna FY2025 Consolidated Balance Sheets [14].

Total debt is $31,463M (short-term $592M plus long-term $30,871M) [15]. Against cash and equivalents of $7,676M plus short-term investments of $1,056M, net debt is $22.7 billion (or $23.8 billion counting cash alone). EBITDA on FY2025 filings is about $12.0 billion — operating income of $9,200M plus $2,775M of depreciation and amortization [16] — and consensus puts actual FY2025 EBITDA at $12,351M. Either way, net debt to EBITDA computes to roughly 1.8–1.9x ($22,731M ÷ $12,351M = 1.84x). That is squarely moderate: above the 0.5x fortress threshold, well below the 3.0x levered line. The 10% default bar applies.

The feature file records this class as unknown because the structured feed carried no FY2025 debt figure; the filed balance sheet does, and it places Cigna in the moderate band.

Stated plainly against that line: 9.80% on FY2025 adjusted FCF against the 10% bar — 20 basis points short. On the three-year average the same company sits 93 basis points over it (10.93%). Cigna straddles the reference line rather than clearing or missing it decisively.

Normalized mid-cycle yield

Managed care is mildly cyclical, not deeply so — there is a medical-cost and underwriting cycle, but no commodity-style swing that leaves a single year unrepresentative. Two things nonetheless make raw FY2025 an imperfect anchor. First, FY2023 adjusted FCF of $9.4 billion was lifted by unusually favorable working capital — pharmacy and other service costs payable rose $2,030M and accounts-payable/accrued liabilities $3,481M that year [17]. Second, FY2024–FY2025 fell inside the industry's elevated-medical-cost stretch, which compressed margins and, with a $597M acquisition year in 2025, pulled adjusted FCF down to $7.5 billion.

The mid-cycle estimate centers those two: the three-year average adjusted FCF of $8,358M ($9,440M, $8,139M and $7,496M ÷ 3), which nets the working-capital high against the cyclical low. On the current $76.5B market cap that is a mid-cycle adjusted yield of ~10.9%. The assumptions are explicit enough to recompute under an alternate window: narrow to the two elevated-cost years FY2024–FY2025 and mid-cycle adjusted FCF falls to ~$7,818M (a 10.2% yield); widen to include consensus FY2026 FCF (net of the ~$0.9B adjustment, ~$8.1B) and it rises. Across every reasonable window the mid-cycle yield lands between about 10.2% and 11%, i.e. at or modestly above the 10% bar. A skeptic who prefers the single depressed FY2025 figure gets 9.8%; one who normalizes gets ~10.9%.

The consensus check

The sell side does not need Cigna's cash flow to recover to clear the bar — it already models it above. On CapIQ estimates dated 22 July 2026, consensus free cash flow (the vendor's free cash flow line, the closest direct proxy to the framework's numerator) runs $9.5B in FY2025 rising to $10.3B by FY2028 — yields of 12.4% to 13.4% on today's market cap.

Consensus estimates (CapIQ), generated 22 Jul 2026; vendor free-cash-flow line and cash-from-operations less capex, mean estimates. As reported in the estimates feed.

Two proxies bracket the answer, and naming which is which matters. The vendor's headline free-cash-flow metric ($9.5B FY2025, a 12.4% yield) sits well above the 10% bar. A plainer construction — consensus cash from operations less capex ($8,238M − $1,300M = $6,938M in FY2025) — yields only 9.1%, just under it, because the vendor's FCF line runs richer than a simple operating-cash-flow-minus-capex build. The gap narrows in the out-years as consensus CFO estimates rise: by FY2027 the CFO-less-capex proxy reaches $9,049M (11.8%) and the vendor line $10,162M (13.3%).

Apply the framework's own ~$0.9 billion adjustment (SBC plus five-year-average acquisitions) to the vendor forward line and the adjusted forward yield is still ~10.6% in FY2026 rising to ~12% by FY2027 — above the bar on the richer proxy, right at it on the conservative one. The setup this describes is fear rather than a fundamentals problem: analysts model FCF that clears or nearly clears the 10% line every forward year, they carry a mean price target of $340.92 against the $284.85 quote (24 analysts, 20 buy/outperform ratings to four holds and no sells), and consensus net debt falls from $23.9B in FY2025 toward $16.0B by FY2027 — deleveraging that would only strengthen the balance-sheet class. Because consensus already sits at or above the bar, no mean-reversion underwrite is required; the risk is not that Cigna must climb back to the line but that the softer CFO-less-capex proxy, if it proves the truer FCF, leaves the current-year yield a point below it.

FCF-to-revenue conversion

The one genuinely deteriorating series in this tab is cash conversion. Reported FCF as a share of revenue has fallen from ~5.5% in 2019–2020 to ~3.0% in 2025.

Reported FCF (operating cash flow − capex) ÷ total revenue. Revenue per the financial feed; cash-flow components from the filed statements [18].

The decline is real but mostly a mix artifact. Revenue rose from $153.6B in 2019 to $274.9B in 2025, the bulk of the growth coming from Evernorth's pharmacy and PBM activity, where drug-cost pass-through inflates the top line at near-zero margin — so the denominator grows faster than any cash-generative business underneath it. The counter-fact that keeps this honest: the numerator has also drifted down in absolute terms, from $10.2B reported (2023) to $8.4B (2025), and adjusted FCF from $9.4B to $7.5B. Some of that is the working-capital and medical-cost story above rather than structural erosion, but the trend does not support treating Cigna as an accelerating cash compounder; it is a large, steady generator whose per-dollar-of-revenue conversion is being diluted by low-margin volume. That distinction — dilution by mix versus decay in the underlying — is what the durability of the cash flows (Durability) turns on.